Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study.

Greenfield, D M; Salooja, N; Peczynski, C; van der Werf, S; Schoemans, H; Hill, K; Cortelezzi, A; Lupo-Stangellini, M; Özkurt, Z N; Arat, M; Metzner, B; Turlure, P; Rovó, A; Socié, G; Mohty, M; Nagler, A; Kröger, N; Dreger, P; Labopin, M; Han, T S; ... (2021). Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone marrow transplantation, 56(11), pp. 2820-2825. Springer Nature 10.1038/s41409-021-01414-7

[img]
Preview
Text
s41409-021-01414-7.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (805kB) | Preview

Metabolic syndrome (MetS) is associated with cardiovascular disease in the general population and is also a potential cardiovascular risk factor in survivors of haematopoietic cell transplantation (HCT). We report an EBMT cross-sectional, multi-centre, non-interventional study of 453 adult HCT patients surviving a minimum of 2 years post-transplant attending routine follow-up HCT and/or late effects clinics in 9 centres. The overall prevalence of MetS was 37.5% rising to 53% in patients >50 years of age at follow-up. There were no differences in rates of MetS between autologous and allogeneic HCT survivors, nor any association with graft-versus-host disease (GvHD) or current immunosuppressant therapy. Notably, there was a significantly higher occurrence of cardiovascular events (CVE, defined as cerebrovascular accident, coronary heart disease or peripheral vascular disease) in those with MetS than in those without MetS (26.7% versus 9%, p < 0.001, OR 3.69, 95% CI 2.09-6.54, p < 0.001), and, as expected, MetS and CVE were age-related. Unexpectedly, CVE were associated with occurrence of second malignancy. Screening for and management of MetS should be integrated within routine HCT long-term follow-up care for both allogeneic and autologous HCT survivors. Further research is warranted, including randomised controlled trials of interventional strategies and mechanistic studies of cardiovascular risk in HCT survivors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0268-3369

Publisher:

Springer Nature

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

08 Oct 2021 15:40

Last Modified:

05 Nov 2021 00:13

Publisher DOI:

10.1038/s41409-021-01414-7

PubMed ID:

34274955

BORIS DOI:

10.48350/159578

URI:

https://boris.unibe.ch/id/eprint/159578

Actions (login required)

Edit item Edit item
Provide Feedback